GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » 5-Year Yield-on-Cost %

XTL Biopharmaceuticals (XTAE:XTLB) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 30, 2025)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals 5-Year Yield-on-Cost %?

XTL Biopharmaceuticals's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for XTL Biopharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



XTAE:XTLB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.715
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of XTL Biopharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, XTL Biopharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

XTL Biopharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of XTL Biopharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

XTL Biopharmaceuticals  (XTAE:XTLB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


XTL Biopharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.